Cannabis and Depression
What the evidence actually says about using cannabis for depressive disorders, separating clinical data from marketing and folklore.
Cannabis is one of the most commonly self-reported 'treatments' for depression, but the clinical evidence is thin and mostly observational. Short-term, some people feel better after using it. Long-term, heavy use is associated with worse depression, not better. There are no high-quality randomized trials showing cannabis treats major depressive disorder. If you're depressed and self-medicating with weed, that's understandable — but it's not a substitute for actual treatment, and in some people it makes things worse.
Not Medical Advice
This article is not medical advice. It summarizes published evidence as of 2024. Depression is a serious illness with effective evidence-based treatments. If you are struggling, talk to a licensed clinician. If you are in crisis, contact emergency services or a suicide prevention hotline (in the US: 988). Do not stop or change prescribed medication based on an encyclopedia article.
Plain-Language Summary
Depression is among the top reasons people give for using cannabis medicinally [1]. The short version of what we know:
- No randomized controlled trial has shown that whole-plant cannabis, THC, or CBD effectively treats major depressive disorder (MDD) No data [2][3].
- Observational studies consistently find that **heavier and more frequent cannabis use is associated with more depression**, not less, especially in adolescents and young adults Strong evidence [4][5].
- Many users report acute mood lift after using cannabis Anecdote. This short-term subjective effect is real, but it is not the same as treating an underlying depressive disorder, and tolerance, withdrawal, and rebound low mood complicate the picture Weak / limited [6].
- Cannabis can interact badly with bipolar disorder and is linked to earlier onset and worse course of illness Strong evidence [7].
In other words: the cultural story ('weed helps with depression') is not supported by the clinical story ('we have no good trials and the long-term data look bad').
What Probably Works
Nothing, specifically, for depression itself. There is no cannabis-based intervention with strong (replicated, randomized, placebo-controlled) evidence for treating depressive disorders No data.
The closest indirect claim is that in patients with chronic pain, treating pain with cannabinoids may improve mood and quality of life as a downstream effect Weak / limited [8]. This is not the same as treating depression — it's treating pain, with mood improving secondarily. Trials in this space are heterogeneous and often unblinded.
What Might Work (Weak or Preliminary Evidence)
- CBD for anxiety-driven low mood: A few small trials show CBD reduces acute anxiety Weak / limited [9]. Because anxiety and depression often co-occur, some clinicians extrapolate that CBD might help mood. The extrapolation is not the same as evidence. There are no adequately powered CBD-for-depression trials in humans.
- Cannabis-assisted sleep in depressed patients: Insomnia worsens depression, and short-term cannabis use can reduce sleep latency Weak / limited [10]. Chronic use disrupts sleep architecture (less REM, rebound on cessation), so this is a short-term tool at best.
- Reducing rumination acutely: Self-report data suggest acute intoxication reduces ruminative thinking Anecdote. No controlled long-term outcome data.
None of this rises to 'cannabis treats depression.' It rises to 'cannabis affects symptoms that overlap with depression, sometimes, short-term.'
What Doesn't Work / Weak Evidence
- 'Indica strains are antidepressant': Folklore. The indica/sativa distinction does not reliably predict chemistry or effects Disputed [11]. See Indica vs Sativa.
- High-THC flower as a mood treatment: Higher THC potency is associated with worse mental health outcomes in observational data, including depressive and psychotic symptoms Strong evidence [12].
- CBD-dominant products marketed for depression: Currently no high-quality human trials supporting an antidepressant effect of CBD No data.
- Microdosing THC as an antidepressant: Popular online claim. No controlled evidence No data.
- 'Cannabis replaces SSRIs': There are no head-to-head trials. Patients who substitute cannabis for prescribed antidepressants do so without an evidence base No data.
What We Don't Know
Genuine open questions:
- Whether specific cannabinoid ratios (e.g., balanced THC:CBD) might help a defined subgroup of depressed patients.
- Whether occasional, low-dose use differs meaningfully from daily heavy use in long-term mood outcomes (most epidemiology lumps these together).
- Whether endocannabinoid system dysfunction is a meaningful subtype of depression that could be targeted pharmacologically — this is an active research area but has not yielded approved therapies [13].
- Whether CBD has antidepressant effects in humans at therapeutic doses (preclinical signals exist; human trials are sparse) Weak / limited [14].
We also don't know much about long-term outcomes in older adults, who are the fastest-growing group of new cannabis users.
Comparison With Standard Treatments
Standard, evidence-based treatments for depression include:
- SSRIs/SNRIs: Modest but real effect sizes vs. placebo, well-replicated Strong evidence [15].
- Cognitive behavioral therapy (CBT) and interpersonal therapy: Comparable to medication for mild-moderate depression Strong evidence [15].
- Exercise: Meaningful antidepressant effect, especially for mild-moderate cases Strong evidence [16].
- For treatment-resistant depression: ECT, ketamine/esketamine, TMS — all with controlled evidence Strong evidence.
Cannabis has nothing in this tier. A patient choosing cannabis instead of these treatments is choosing an option with weaker evidence, more uncertainty, and known harms in vulnerable subgroups.
Risks
Risks specifically relevant to depressed patients:
- Worsening depression with heavy use: Dose-response relationship in longitudinal data Strong evidence [4][5].
- Increased suicidal ideation and attempts, particularly in adolescents and young adults using frequently Strong evidence [17].
- Cannabis use disorder (CUD): Roughly 1 in 10 users overall, higher in those who start young or use daily Strong evidence [18]. CUD is itself associated with worse depression.
- Bipolar disorder: Cannabis use is linked to earlier onset, more manic episodes, and worse outcomes Strong evidence [7]. People with bipolar depression should avoid cannabis.
- Psychosis risk in those with personal or family history Strong evidence [12].
- Withdrawal: Irritability, low mood, sleep disturbance, and anhedonia for 1–2 weeks after stopping heavy use Strong evidence [19] — easily mistaken for 'depression returning,' which reinforces continued use.
- Drug interactions: CBD especially can interact with SSRIs and other psychiatric medications via CYP450 enzymes Strong evidence [20].
See also Cannabis Use Disorder and Cannabis and Anxiety.
Sources
- Peer-reviewed Sexton, M., Cuttler, C., Finnell, J. S., & Mischley, L. K. (2016). A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy. Cannabis and Cannabinoid Research, 1(1), 131–138.
- Government National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press.
- Peer-reviewed Black, N., Stockings, E., Campbell, G., et al. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The Lancet Psychiatry, 6(12), 995–1010.
- Peer-reviewed Gobbi, G., Atkin, T., Zytynski, T., et al. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis. JAMA Psychiatry, 76(4), 426–434.
- Peer-reviewed Lev-Ran, S., Roerecke, M., Le Foll, B., et al. (2014). The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychological Medicine, 44(4), 797–810.
- Peer-reviewed Cuttler, C., Spradlin, A., & McLaughlin, R. J. (2018). A naturalistic examination of the perceived effects of cannabis on negative affect. Journal of Affective Disorders, 235, 198–205.
- Peer-reviewed Gibbs, M., Winsper, C., Marwaha, S., et al. (2015). Cannabis use and mania symptoms: a systematic review and meta-analysis. Journal of Affective Disorders, 171, 39–47.
- Peer-reviewed Whiting, P. F., Wolff, R. F., Deshpande, S., et al. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456–2473.
- Peer-reviewed Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.
- Peer-reviewed Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports, 19(4), 23.
- Peer-reviewed Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE, 17(5), e0267498.
- Peer-reviewed Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry, 6(5), 427–436.
- Peer-reviewed Hill, M. N., & Gorzalka, B. B. (2009). The endocannabinoid system and the treatment of mood and anxiety disorders. CNS & Neurological Disorders - Drug Targets, 8(6), 451–458.
- Peer-reviewed Silote, G. P., Sartim, A., Sales, A., et al. (2019). Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. Journal of Chemical Neuroanatomy, 98, 104–116.
- Peer-reviewed Cipriani, A., Furukawa, T. A., Salanti, G., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366.
- Peer-reviewed Schuch, F. B., Vancampfort, D., Richards, J., et al. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51.
- Peer-reviewed Borges, G., Bagge, C. L., & Orozco, R. (2016). A literature review and meta-analyses of cannabis use and suicidality. Journal of Affective Disorders, 195, 63–74.
- Peer-reviewed Hasin, D. S., Saha, T. D., Kerridge, B. T., et al. (2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12), 1235–1242.
- Peer-reviewed Bonnet, U., & Preuss, U. W. (2017). The cannabis withdrawal syndrome: current insights. Substance Abuse and Rehabilitation, 8, 9–37.
- Peer-reviewed Brown, J. D., & Winterstein, A. G. (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Bipolar Disorder — What the evidence actually says about using cannabis for mania, depression, and mood stabi...
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...